Objective-Subjects with diabetes mellitus are at high risk for developing atherosclerosis through a variety of mechanisms.
S ubjects with diabetes mellitus are at 2-to 6-fold greater risk of developing atherosclerosis than nondiabetic individuals, 1,2 constituting the main cause of morbidity and mortality. 3, 4 In diabetes mellitus, an emerging view is that events leading to accelerated atherosclerosis in affected subjects are underway before the diagnosis of the disease. 5 Thus, an intensive search for new therapeutic targets in diabetic atherosclerosis is needed. These considerations led us to investigate molecular mechanisms by which diabetes mellitus accelerates atherosclerosis.
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The ubiquitous enzyme protein kinase C (PKC), a family of ≥12 isoforms of serine and threonine kinases, has been linked to the pathogenesis of vascular injury. Although several PKC isoforms are expressed in vascular tissue, in the rodent model of diabetes mellitus, there is a preferential activation of PKCβII in the aorta and heart. 6 Increasing evidence links hyperglycemia to diabetic microvascular complications via activation of PKCβ, [7] [8] [9] but PKCβ-dependent mechanisms have yet to be elucidated in macrovascular complications of diabetes mellitus. We previously reported that PKCβ −/− / ApoE −/− mice displayed less atherosclerosis than ApoE −/− mice and demonstrated links between activation of PKCβ and nondiabetic atherosclerosis. 10 In parallel, our previous findings revealed that activated PKCβ, especially βII isoform, is a critical upstream regulator of early growth response 1 (Egr-1) in response to vascular stress, such as hypoxia, 11, 12 ischemia/ reperfusion, 13 and nondiabetic atherosclerosis. 10 Egr-1, in turn, acts as a master switch coordinating expression of proinflammatory cytokines, chemokines, procoagulant molecules, cell adhesion molecules, and matrix metalloproteinase-2. 10, 14, 15 However, macrovascular disease in diabetes mellitus is manifested by more accelerated and progressive atherosclerosis, which is more widely distributed. Because the metabolism of glucose results in production of activators of PKCβ, it was logical to investigate the role of PKCβ in modulation of atherosclerosis in diabetes mellitus.
In this study, we hypothesized that in diabetes mellitus, enhanced activation of PKCβ is critical to augmented expression of a broad range of inflammatory mediators and increased phosphorylation of signaling molecules in the diabetic vascular wall, processes that contribute to accelerated atherosclerotic lesion initiation and progression in diabetes mellitus. Here, we tested these concepts in homozygous ApoE −/− and PKCβ −/− / ApoE −/− mice made diabetic with streptozotocin (stz). [16] [17] [18] In addition, we tested the effects of a PKCβ inhibitor, ruboxistaurin, on atherosclerosis in diabetic ApoE −/− mice. Furthermore, in vitro, we tested the effects of small interfering RNA to Egr-1 or inhibitors of PKCβ, extracellular signal-regulated kinase 1/2 (ERK1/2), Jun-N-terminus kinase (JNK), and p38 mitogenactivated protein (MAP) kinase on high-glucose-induced proinflammatory gene expression in U937 macrophages.
Materials and Methods
Materials and Methods are available in the online-only Supplement.
Results

Enhanced Activation of PKCβII in Aorta of Diabetic ApoE −/− Mice
To dissect the contribution of PKCβ in the pathogenesis of diabetes mellitus-accelerated atherosclerosis, we first assessed the extent of activation of the PKCβII isoform in the aortas of diabetic ApoE −/− mice at age 10 weeks, a time point before the development of significant atherosclerosis. Compared with nondiabetic ApoE −/− mice, diabetic ApoE −/− mice displayed higher levels of phosphor-PKCβII in membranous fractions versus nondiabetic ApoE −/− mice ( Figure 1 ; P<0.0001), although nondiabetic ApoE −/− mice showed an increase in phosphor-PKCβII in membranous fractions versus wild-type mice (Figure 1 ; P<0.0001). In contrast, no change in phosphor-PKCδ was detected in the membranous fraction from wildtype, nondiabetic ApoE −/− , and diabetic ApoE −/− mice. Loading controls using anti-β-actin IgG demonstrated identical protein loading ( Figure 1 ). These observations indicated enhanced activation of PKCβII in diabetic ApoE −/− mice.
Effects of PKCβ Deletion on Accelerated Atherosclerosis in Diabetic ApoE −/− Mice
Mice were rendered diabetic at age 6 weeks and fed normal rodent chow. At age 14 weeks, mean atherosclerotic lesion area at the aortic sinus was 34 362.17±7114.49 µm 2 (n=13) in nondiabetic ApoE −/− mice. Diabetes mellitus, as expected, led to an ≈1.91-fold increase in lesion area in diabetic ApoE −/− mice (65 585.5±4345.13 µm 2 ; n=14) compared with nondiabetic ApoE −/− mice; P<0.001 (Figure 2A ). In contrast, atherosclerotic lesion area at the aortic sinus was ≈38% lower in diabetic PKCβ −/− /ApoE −/− (40 611.10±4767.72 µm 2 ; n=15) compared with that in diabetic ApoE −/− mice; P<0.001 ( Figure 2A ). Diabetic PKCβ −/− /ApoE +/+ animals displayed no atherosclerotic lesions (not shown). The effects of PKCβ on diabetic atherosclerosis were sustained beyond the earliest stages of lesion formation and accelerated by aging. Specifically, at age 20 weeks, similar results were observed; however, the differences between double-null and singlenull ApoE −/− mice were even more striking: mean atherosclerotic lesion area was ≈55% lower in diabetic PKCβ −/− / ApoE −/− mice (99 259.62±11 138.17 μm 2 ; n=13) versus diabetic ApoE −/− animals (220 952.86±14 653.50 μm 2 ; n=14); P<0.0001 ( Figure 2B ). Sudan IV stain for aortic en face area, at age 20 weeks, also showed greater lesion area in diabetic ApoE −/− mice compared with nondiabetic ApoE −/− mice (P<0.05; Figure 2C ), and this was reduced in diabetic PKCβ −/− /ApoE −/− mice compared with diabetic ApoE −/− animals (P<0.05; Figure 2C ). In parallel with decreased atherosclerotic lesion area, the lesion complexity index also was significantly lower in diabetic PKCβ −/− /ApoE −/− mice versus diabetic ApoE −/− mice at age 20 weeks (0.562±0.05 versus 0.966±0.006; P<0.0001; Figure 2D ).
Effects of PKCβ Inhibition on Atherosclerosis in Diabetic ApoE −/− Mice
If PKCβ activation contributed to accelerated atherosclerosis development, its inhibition should reduce lesions. We tested a selective inhibitor of this enzyme, ruboxistaurin. When ApoE −/− male mice expressing PKCβ were treated with ruboxistaurin from age 5 to 20 weeks, mean atherosclerotic lesion area at the aortic sinus was ≈59% lower in diabetic ApoE −/− male mice fed ruboxistaurin (106 682.5±13 626.72 μm 2 ; n=13) versus diabetic ApoE −/− male mice fed vehicle chow (260 267.86±22 926.95 μm 2 ; n=14; P<0.0001; Figure 3A ). In parallel, the complexity index was significantly lower in diabetic ApoE −/− mice fed ruboxistaurin versus vehicle (0.487±0.052 versus 0.978±0.009; P<0.0001; Figure 3B ). 
Effects of PKCβ Deletion/Inhibition on Glycemia and Lipid in Diabetic ApoE −/− Mice
We examined factors that might account for the beneficial effects of PKCβ deletion or inhibition. Diabetic mice displayed a significantly higher plasma glucose level, cholesterol, and triglyceride than nondiabetic mice ( Table I in the online-only Data Supplement). Importantly, no statistically significant differences were observed in levels of plasma glucose, cholesterol, and triglyceride in diabetic PKCβ −/− / ApoE −/− animals versus diabetic ApoE −/− mice or in diabetic ApoE −/− mice fed ruboxistaurin versus vehicle chow at age 14 weeks (data not shown) and at age 20 weeks ( Table I in 
Effects of PKCβ Deletion on Vascular Expression of Inflammatory Mediators and Activation of MAP Kinase in Diabetic ApoE −/− Mice
We sought to identify the specific mechanisms by which PKCβ contributed to early atherogenesis in diabetic ApoE −/− mice. Aortic RNA was prepared from nondiabetic and diabetic ApoE −/− and PKCβ −/− /ApoE −/− mice at age 10 weeks, a time point before atherosclerotic lesion development. The RNA samples were subjected to pathway-focused gene expression profiling using Mouse Atherosclerosis RT2 Profiler PCR Array. Our data revealed a progressive increase in expression of 14 of 84 stress-responsive genes ( Table II in the online-only Data Supplement), including chemokines (Ccl2, Ccr1, and Ccr2), cytokines (IL1α, IL1b, IL1r2, and Spp1), transmembrane proteins (Itgαx and Itgb2), Matrix metallopeptidase (Mmp3), signal transducer (Msr1), and adhesion molecules (Sele, Sell, Selp, and Selplg) in diabetic ApoE −/− mice. In contrast, those gene transcripts were dramatically reduced in diabetic PKCβ −/− /ApoE −/− mice.
Next, to further validate a progressive increase in gene expression in diabetic ApoE −/− mice, primers were chosen for real-time polymerase chain reaction analysis if upregulation of the gene was ≥2-fold higher in aortas of diabetic ApoE −/− mice compared with that of nondiabetic ApoE −/− mice at age 10 weeks or ≤2-fold lower in aortas of diabetic PKCβ −/− / ApoE −/− mice compared with that of diabetic ApoE −/− mice. As indicated in Figure 4A , all of the above gene expression changes in aortas of diabetic ApoE −/− mice were verified; there was a significant increase in each of these genes in diabetic ApoE −/− aortas (#P≤0.05, *P≤0.01, and ^P≤0.001) compared with nondiabetic ApoE −/− mice at age 10 weeks, whereas these gene expression levels in diabetic aortas of PKCβ −/− /ApoE −/− mice were not significantly different compared with that of nondiabetic ApoE −/− mice at age 10 weeks. Furthermore, as indicated in Figure 4A , quantitative real-time polymerase chain reaction confirmed that the progressive increase in gene expression of those 14 inflammatory mediators in diabetic ApoE −/− mice was significantly reduced in diabetic PKCβ −/− / ApoE −/− mice (##P≤0.05, **P≤0.01, and ^^P≤0.001). In contrast, as indicated in Figure 4B , some representative genes, such as Ace, Itga2, and PdgFrb, were not altered in diabetic mice and not affected by PKCβ deficiency.
In addition, we determined whether PKCβ modulated the expression of Egr-1 and activation of signaling mechanisms, such as ERK1/2 and JNK MAP kinases in the vessel wall of diabetic ApoE −/− mice at age 10 weeks. Real-time polymerase chain reaction revealed that transcripts for Egr-1 were significantly increased in aortas of diabetic ApoE −/− mice compared with nondiabetic ApoE −/− mice (P<0.01; Figure 4C ). In contrast, transcripts for Egr-1 were significantly decreased in aortas of diabetic PKCβ −/− /ApoE −/− mice versus diabetic ApoE −/− mice (P<0.01; Figure 4C ). Immunoblots displayed that Phosphor-ERK1/2 (P-ERK1/2; P<0.01; Figure 4D ) and phosphor-JNK (P-JNK; P<0.01; Figure 4E ) were significantly lower in the aortas of diabetic PKCβ −/− /ApoE −/− mice versus diabetic ApoE −/− mice. Loading controls using anti-total ERK1/2 (T-ERK) and anti-total JNK (T-JNK) IgG demonstrated identical protein loading ( Figure 4D and 4E).
Effects of PKCβ Deletion on Inflammatory-Appearing Lesions in Diabetic ApoE −/− Mice
On the basis of the above findings that the increased expression of integrin, alpha X 9complement component 3 receptor 4 subunit (Itgax) transcripts was dependent on PKCβ activation in aortas of diabetic ApoE −/− mice, we sought to determine whether PKCβ-dependent Itgax expression contributes to inflammatory-appearing lesions in the development of diabetic atherosclerosis. CD11c (ITGAX), encoding integrin alpha X chain protein, expressed on monocytes/macrophages and dendritic cells (DCs). 19 Immunofluorescence staining with a macrophage marker, anti-monocyte + macrophage antibody (MOMA-2) IgG, showed that infiltration of macrophages in atherosclerotic lesions of aortic sinus was significantly lower in diabetic PKCβ −/− /ApoE −/− mice ( Figure 5A ) compared with diabetic ApoE −/− mice ( Figure 5B ) at age 20 weeks (P<0.01; Figure 5D ). Next, colocalization of CD11c and MOMA-2 revealed that the immunoreactivity for CD11c was predominantly present in the macrophages in the atherosclerotic lesions of diabetic ApoE −/− mice at age 20 weeks ( Figure 5B and 5C). However, CD11c-expressing cells were significantly lower in diabetic PKCβ −/− /ApoE −/− mice ( Figure 5A ) compared with diabetic ApoE −/− mice ( Figure 5B ) at age 20 weeks (P<0.01; Figure 5E ). Isotype control immunohistochemistry with isotype-matched hamster IgG and rat IgG showed no staining ( Figure 5A-5C ). These data suggest an important role of PKCβ in modulating CD11c expression in macrophages, which potentially contributed to the development of diabetic atherosclerosis.
Effects of High Glucose on PKCβ-Dependent Signaling Pathways in U937 Macrophages
Stimulated by the above findings, to further dissect the molecular mechanisms by which PKCβ activation upregulated gene expression in monocytes/macrophages in settings characterized by high levels of glucose, we used human U937 macrophages as an in vitro model system. Real-time polymerase chain reaction analysis of total RNA from U937 cells exposed to high glucose demonstrated an ≈3.72-, 2.88-, 2.95-, and 3.68-fold increase in Egr-1, CD11c, chemokine (C-C motif) ligand 2 (CCL2), and interleukin (IL)-1β transcripts, respectively, compared with U937 cells cultured in low glucose (P<0.0001; Figure 6A-6D) , in a manner significantly suppressed by the inhibition of PKCβ (LY379196, 30 nmol/L; P<0.0001 or P<0.001; Figure 6A -6D) and ERK1/2 (U0126; 5 µmol/L; P<0.0001; Figure 6A -6D). However, high-glucoseinduced CD11c expression in U937 cells was not suppressed by the inhibitors of JNK (SP600125; 20 µmol/L) and p38 (SB203550; 20 µmol/L; Figure 6B ). High-glucose-induced Egr-1 expression in U937 cells was suppressed by the inhibitor of JNK (P<0.0001; Figure 6A ), not by an inhibitor of p38 ( Figure 6A) , and high-glucose-induced increase in CCL2 and IL-1β expression was suppressed by the inhibitors of JNK and p38 (P<0.0001; Figure 6C and 6D ).
Next, we tested whether Egr-1, a downstream target of ERK1/2 and PKCβ in vascular stress, is required for highglucose-induced expression of CD11c, CCL2, and IL-1β in U937 macrophages. Introduction of small interfering RNA to knockdown Egr-1 expression in U937 cells blunted the high-glucose-induced upregulation of CD11c, CCL2, and IL-1β transcripts (P<0.0001; Figure 6B -6D) but not scramble control (data not shown). These data suggest that the PKCβ pathway modulates CD11c, CCL2, and IL-1β upregulation, at least in part via activation of ERK1/2 and Egr-1.
Discussion
We report an important role for PKCβ in acceleration of initiation and progression of atherosclerosis in diabetic ApoE −/− mice. Activation of PKCβII, indicated by translocation from the cytosol to the plasma membrane, has been shown in aortas of nondiabetic ApoE −/− mice versus wild-type C57BL/6 animals in our previous studies. 10 Our present data demonstrated a significant increase in phosphor-PKCβII in the membrane fractions from aortas of diabetic ApoE −/− mice versus nondiabetic ApoE −/− mice at age 10 weeks, a time point before the development of significant atherosclerosis. These findings suggest that enhanced activation of PKCβII in a hyperglycemic and hyperlipidemic environment may reflect a response of the blood vessel wall to superimposed biochemical and metabolic stresses. Consistent with important roles for PKCβ in accelerated atherosclerosis in diabetes mellitus, our findings demonstrated that genetic deletion or pharmacological inhibition of PKCβ in diabetic ApoE −/− mice significantly diminished atherosclerotic lesion areas and complexity indices, but did not affect the levels of glucose, cholesterol, and triglyceride. These findings suggest that modulation of diabetic atherosclerosis by PKCβ deletion or blockade was independent of changes in glucose and lipids. Because the traditional therapeutic approaches by glycemic control lacks clearly an established benefit in macrovascular disease, our findings may suggest important implications for blockade of PKCβ signaling pathway by using the PKCβ inhibitor ruboxistaurin for the management of diabetic atherosclerosis. Both elevated glucose and lipids contribute to increased inflammation in diabetes mellitus. 20, 21 We assessed the mechanisms by which PKCβ plays a crucial role in the accelerated initiation and progression of atherosclerotic lesion areas in diabetes mellitus. Our data demonstrated that increased expression of inflammatory mediators and activation of signaling MAP kinases, including proinflammatory transcription factor Egr-1, chemokines (Ccl2, Ccr1, and Ccr2), cytokines (IL-1α, IL-1β, IL-1γ2, and Spp1), transmembrane proteins (Itgax and Itgb2), matrix metallopeptidase (Mmp3), signal transducer (Msr1), adhesion molecules (Sele, Sell, Selp, Selplg, and Spp1), in early atherogenesis in the aortas of diabetic ApoE −/− mice is dependent on the state of glycemia and the state of PKCβ expression because genetic deletion of PKCβ in diabetic ApoE −/− mice dramatically attenuated expression of those inflammatory mediators and signaling molecules. Our findings reveal a critical role for PKCβ-dependent upregulation of inflammatory mediators and signaling molecules in initiating steps of atherogenesis in the diabetic vascular wall, leading to enhanced progression of atherosclerotic complications.
Given the inflammatory basis of atherosclerosis, macrophages have been considered to be important immune effector cells, which contribute to and promote the development of atherosclerotic plaques. [22] [23] [24] An in vitro study showed that macrophages, when treated with oxidatively modified lipids, differentiate into foam cells and in the process acquire expression of DC marker. 25 One of the DC markers, CD11c, which is not an exclusive marker of DCs but can also be found on macrophages, 19 has been implicated as a functional integrin in human and mouse models. 26, 27 Our data revealed that the increased CD11 + cells in atherosclerotic lesions in diabetic ApoE −/− mice are, at least in part, macrophages based on colocalization with MOMA-2. In concurrence with these findings, the cholesterol-rich diet-fed Ldlr −/− mice displayed foam cells expressing DC marker CD11c, 28 and AopE −/− mice showed an increased number of CD11c + cells with the progression of atherosclerosis. 24, 29 Also, high-fat diet-fed ApoE −/− mice displayed increased CD11c + cells, which were colocalized with MOMA-2 in atherosclerotic lesions. 27 Interestingly, we provide the first evidence that the increase in gene expression of Itgax (CD11c) in diabetic ApoE −/− mice expressing PKCβ was suppressed in diabetic ApoE −/− mice devoid of PKCβ. In parallel, decreased % macrophages/total lesion area and % CD11c + cells/total lesion area were evident in diabetic PKCβ −/− /ApoE −/− mice versus diabetic ApoE −/− mice. In addition, we demonstrated that PKCβ regulated increased expression of Egr-1 and phosphorylation of ERK1/2 and JNK MAP kinases in early atherogenesis in diabetes mellitus. Consistent with these observations, high-glucose-induced increase in Egr-1 transcripts in U937 macrophages was blunted by the inhibitors of PKCβ, ERK1/2, and JNK, but not by the inhibitor of p38. Because Egr-1 has been demonstrated to play an important role in nondiabetic atherosclerosis, 15, 30, 31 and it is one of the key downstream target genes of PKCβ and ERK1/2 or JNK in the response to hypoxia, 11, 12, 32 ischemia, 13 acute vascular injury, 33, 34 and in nondiabetc atherosclerosis, 10 our current data suggest that PKCβ mediates upregulation of Egr-1, at least in part, via increased phosphorylation of ERK1/2 and JNK in early atherogenesis in diabetes mellitus. Furthermore, because there are 2 putative Egr-1-binding motifs in the proximal region of the CD11c (p150,95) promoter, which may participate in the regulation of CD11c expression based on our TRANSFAC database search, 35 we examined the effects of high-glucose-stimulated PKCβ-dependent signaling pathway on CD11 gene expression in U937 macrophages. The knockdown of Egr-1 expression by small interfering RNA or inhibition of PKCβ and ERK1/2, but not JNK and p38, resulted in attenuation of high-glucose-induced CD11c expression in U937 macrophages. These data suggest that PKCβ regulates CD11 expression in the inflammatory macrophages in atherosclerosis associated with diabetes mellitus, at least in part, via activation of Egr-1 and ERK1/2 signaling pathway. Studies are underway to further probe the CD11c promoter sites by electrophoretic mobility shift and supershift assays and the chromatin immunoprecipitation assays to establish functionality.
Consistent with our other observations, we showed ample evidence of the involvement of other inflammatory components in the inflammatory and pathological processes of atherosclerosis. One of the chemoattractants implicated in early atherogenesis is monocyte chemoattractant protein-1 (MCP-1/ CCL2), which binds to C-C chemokine receptor 2 (CCR2). 36 MCP-1/CCL2 is highly expressed in atherosclerotic plaques 36 and mediates macrophage recruitment in the atheromatous lesion. Given the importance of MCP-1/CCR2 pathway in the process of atherosclerosis, our findings may have important implications in suppression of MCP-1/CCR2 pathway because we demonstrated that genetic deletion of PKCβ attenuated upregulation of MCP-1/CCL2 and CCR2 in vascular tissues of diabetic ApoE −/− mice at age 10 weeks, a time point linked to an early stage of atherogenesis. Because increased CD11c expression in adipose tissue and blood in both mice and humans was found as a consequence of elevated MCP-1 levels secreted by adipose tissue, 37 correlations or interactions between CD11c and MCP-1 will be tested in future studies in vascular inflammation in diabetic atherosclerosis. In addition, a large number of proinflammatory cytokines has been shown to be expressed in human atherosclerotic lesions, particularly in association with infiltrating monocytes and macrophages. 38 IL-1 has been implicated as a regulatory protein in the development and clinical sequelae of atherosclerosis. 39 IL-1β is produced by activated macrophages and considered a master switch of inflammation. 40 IL-1β and its related parent IL-1α have both been implicated in the pathogenesis of atherosclerosis in previous studies. 40 Engagement of CD11c β2 integrin by antibodies was reported to induce IL-1β production on primary human monocytes. 41 The mechanisms instigating and perpetuating inflammatory responses have been studied extensively; however, less is known about the mechanisms governing the resolution of inflammation. We demonstrated that all of the above inflammatory mediators were modulated by vascular activation of PKCβ because they were dramatically Figure 6 . Impact of high glucose and protein kinase C (PKC)β-dependent signaling pathways on the expression of inflammatory mediators in U937 macrophages. U937 cells were seeded and exposed to 5 mmol/L (low, LG) or 25 mmol/L (high, HG) glucose in the absence or presence of small interfering RNA (siRNA) to Egr-1 or the inhibitors of PKCβ, extracellular signal-regulated kinase 1/2 (ERK1/2), Jun-N-terminus kinase (JNK), and p38. Cells were harvested followed by RNA isolation. Real-time PCR analysis of gene expression was performed. Data are represented as the relative gene expression of Egr-1 (A), CD11c (B), CCL2 (C), and IL-1β (D) normalized to 18s rRNA. *P<0.001, the level of gene expression in U937 macrophages exposed to high glucose vs low glucose; ^P<0.001; ^^P<0.01; and #not significant (NS), the level of gene expression in U937 macrophages exposed to high glucose with the treatment of inhibitors or siRNA vs nontreatment. attenuated in diabetic ApoE −/− mice devoid of PKCβ. Based on our previous findings that MCP-1/CCL2 and IL-1β have been demonstrated as downstream target genes of Egr-1 in atherosclerosis in euglycemia, 15 and on our current in vitro data that the knockdown of Egr-1 expression by small interfering RNA or inhibition of PKCβ, ERK1/2, JNK, and p38 led to attenuation of high-glucose-induced CCL2 and IL-1β expression in U937 macrophages, we suggest that PKCβ regulates increased expression of CCL2 and IL-1β, at least in part, via activation of ERK1/2/Egr-1 and JNK/Egr-1 or p38 signaling pathways in atherosclerosis in diabetes mellitus. Although the exact mechanisms by which PKCβ regulates these inflammatory mediators in the development of diabetic atherosclerosis are also the subject of ongoing investigation, our present study may shed light on the effectiveness of PKCβ blockade as a strategy to protect the stressed vascular system from irreversible injury caused by inflammatory response in human atherosclerotic disease, especially in diabetes mellitus.
Although a growing body of evidence from animal and human studies indicates beneficial effects of PKCβ inhibition on microvascular parameters, 9, 42, 43 our studies have examined the effects of PKCβ inhibitor, ruboxistaurin, on macrovascular disease in diabetes mellitus. Our data provide the first evidence that pharmacological blockade of PKCβ by the PKCβ inhibitor, ruboxistaurin, significantly attenuated atherosclerotic lesion areas and complexity indices in diabetic ApoE −/− mice. This work raises the possibility that blockade of the PKCβ by a pharmacological inhibitor, ruboxistaurin, may attenuate neointimal expansion, vascular injury, or damage triggered by inflammatory and pathological processes during the development of atherosclerosis in diabetes mellitus.
In summary, these data link enhanced activation of PKCβ to diabetes mellitus-accelerated atherosclerosis via a mechanism that includes modulation of vascular expression of inflammatory mediators and activation of signaling MAP kinases involved in inflammatory responses, processes that contribute to acceleration of vascular inflammation and atherosclerosis in diabetes mellitus. We have uncovered a novel role for PKCβ in modulating CD11c expression and inflammatory responses of macrophages in the development of diabetic atherosclerosis. Thus, a better understanding of the inflammatory mechanisms by which PKCβ contributes to such processes in the vessel wall could be relevant to devise preventive and therapeutic strategies for diabetic atherosclerosis. In addition, based on our demonstration that pharmacological inhibition of PKCβ reduced lesion size, we suggest that these studies may provide the basis for potential therapeutic application of PKCβ antagonism (ruboxistaurin) to diabetic atherosclerosis.
Our findings show a critical role for protein kinase C (PKC)β-dependent upregulation of inflammatory mediators and signaling molecules in initiating steps of atherogenesis in the diabetic vascular wall, leading to enhanced progression of atherosclerotic complication. Interestingly, our data provide the first evidence that PKCβ modulates CD11c expression and inflammatory responses of macrophages in the development of diabetic atherosclerosis. Thus, a better understanding of PKCβ-dependent inflammatory mechanisms in the vessel wall could be relevant to devise preventive and therapeutic strategies for diabetic atherosclerosis. Furthermore, our demonstration that pharmacological inhibition of PKCβ reduced lesion size may provide the basis for potential therapeutic application of PKCβ antagonism (ruboxistaurin) to diabetic atherosclerosis.
Significance
